Injection-meal interval: recommendations of diabetologists and how patients handle it.
about
Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitusInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical ExperiencePharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study.Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.Insulin aspart: a review.Inhaled insulin (Exubera): Combining efficacy and convenience.Premixed insulin treatment for type 2 diabetes: analogue or human?Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type 2 diabetes and human insulin.Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?Ultrafast-acting insulins: state of the artEffect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal.Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes.Pharmacokinetics and pharmacodynamics of insulin glargine-insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals.Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes.Pharmacological Properties of Faster-Acting Insulin Aspart.
P2860
Q26471380-0A076C9C-3C65-45A3-8E6B-B538C8439B5BQ28085428-1FD79729-EB28-4A94-BB13-1FA2A3BA2594Q33658772-36B6AC18-F6DB-49CE-968E-7AB87103A96DQ35337607-B5D50BA9-1868-48A6-95A1-E817BDECFBC5Q35673057-2F82127A-8D7B-42CF-899C-B9C04C2F34A8Q36051244-566B4083-B122-4B76-B9C1-804CF14FEEA8Q36506133-0FFDBCC8-057E-4A2E-8144-03F97B188080Q36541464-EFAC5E11-B843-47A0-B6B5-17B7E3E8A73EQ36609772-4954196B-191D-477B-BDA0-F3BE2B581B17Q36679610-52E9E347-A474-48B1-9A72-4776DD70BBCAQ36909524-CD85361C-958D-4ACB-ADA2-AB2F49199011Q36942084-99B2A877-4B9E-46F7-A5FE-073BE04ECC1FQ37320243-ECCB2BDE-2F2F-4EF9-98F0-8EAC89EAA1D8Q37689902-1EFD2801-5E93-498A-BC87-20B5BF7A608DQ37742600-30D41AE3-26AC-4306-B0B8-48212C1FEEA1Q38008005-E95EE315-A299-4F4B-853C-221681CBE859Q38037727-D4EF0868-1BCB-4AC2-BDC8-843134DED815Q40573593-4CD658D5-4C6E-41B1-B101-EAB50A08F24FQ42676804-3172FAEA-6385-4CF2-95F7-1EF8D423098DQ44655656-085C58D0-4FF5-4C74-BAED-4328AB44AD77Q44847761-903516F6-86B6-4453-8CA6-8F82BD374337Q44946403-10421D37-BEBD-44F9-A2BF-7443CEED191BQ45729286-0F5E98D5-8940-483D-8306-F2A6FE9C46D3Q46066342-47211A0D-DBE8-4041-AE2F-A70D5AE5B493Q47937602-12F98A63-D886-4B41-9688-0A416F286340
P2860
Injection-meal interval: recommendations of diabetologists and how patients handle it.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@en
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@nl
type
label
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@en
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@nl
prefLabel
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@en
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@nl
P1476
Injection-meal interval: recommendations of diabetologists and how patients handle it.
@en
P2093
Heinemann L
Overmann H
P304
P356
10.1016/S0168-8227(98)00132-6
P577
1999-02-01T00:00:00Z